A block deal of 2.86 lakh shares was executed at Rs 1,085.05 per share. Another block deal of 2.86 lakh shares was executed at Rs 1,086.30 per share. The two block deals constitute 0.43% of Divi's Laboratories' equity.
Meanwhile, the BSE Sensex was up 50.70 points or 0.26% at 19,374.50.
On BSE, 5.83 lakh shares were traded in the counter as against average daily volume of 40,294 shares in the past one quarter.
The stock hit a high of Rs 1,099.20 and a low of Rs 1,072 so far during the day. The stock had hit a 52-week low of Rs 711 on 27 February 2012. The stock had hit a record high of Rs 1,233 on 30 November 2012.
The stock had underperformed the market over the past one month till 27 December 2012, sliding 7.78% compared with the Sensex's 2.56% rise. The scrip had also underperformed the market in past one quarter, rising 1.58% as against Sensex's 4.01% gain.
The large-cap company has equity capital of Rs 26.55 crore. Face value per share is Rs 2.
Divi's Laboratories' net profit rose 11.2% to Rs 117.97 crore on 33.6% growth in net sales to Rs 472.60 crore in Q2 September 2012 over Q2 September 2011.
Divi's Laboratories' product portfolio comprises generic active pharmaceutical ingredients (APIs) and custom synthesis of APIs, intermediates and specialty ingredients for innovator pharma giants. Custom synthesis also includes peptide building blocks (protected amino acids).
Powered by Capital Market - Live News
